NO995617L - Anvendelse av en CD40:CD154 bindingsforstyrrer for å forhindre mot-adaptive immunresponser, spesielt transplantatavstoetning - Google Patents

Anvendelse av en CD40:CD154 bindingsforstyrrer for å forhindre mot-adaptive immunresponser, spesielt transplantatavstoetning

Info

Publication number
NO995617L
NO995617L NO995617A NO995617A NO995617L NO 995617 L NO995617 L NO 995617L NO 995617 A NO995617 A NO 995617A NO 995617 A NO995617 A NO 995617A NO 995617 L NO995617 L NO 995617L
Authority
NO
Norway
Prior art keywords
immune responses
transplant rejection
adaptive immune
binding inhibitor
prevent counter
Prior art date
Application number
NO995617A
Other languages
English (en)
Other versions
NO995617D0 (no
Inventor
Allan D Kirk
David M Harlan
David W Thomas
Michael Kauffman
Linda Brukly
Original Assignee
Biogen Inc
Us Navy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, Us Navy filed Critical Biogen Inc
Publication of NO995617D0 publication Critical patent/NO995617D0/no
Publication of NO995617L publication Critical patent/NO995617L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO995617A 1997-05-17 1999-11-16 Anvendelse av en CD40:CD154 bindingsforstyrrer for å forhindre mot-adaptive immunresponser, spesielt transplantatavstoetning NO995617L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4679197P 1997-05-17 1997-05-17
US4938997P 1997-06-11 1997-06-11
US8514598P 1998-05-12 1998-05-12
PCT/US1998/010075 WO1998052606A1 (en) 1997-05-17 1998-05-15 Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection

Publications (2)

Publication Number Publication Date
NO995617D0 NO995617D0 (no) 1999-11-16
NO995617L true NO995617L (no) 2000-01-17

Family

ID=27366975

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995617A NO995617L (no) 1997-05-17 1999-11-16 Anvendelse av en CD40:CD154 bindingsforstyrrer for å forhindre mot-adaptive immunresponser, spesielt transplantatavstoetning

Country Status (20)

Country Link
US (2) US20020119150A1 (no)
EP (1) EP0980259A1 (no)
JP (1) JP2002500648A (no)
KR (1) KR100575069B1 (no)
CN (1) CN1202864C (no)
AU (1) AU735592B2 (no)
BG (1) BG64841B1 (no)
BR (1) BR9809641A (no)
CA (1) CA2291156A1 (no)
EA (1) EA002549B1 (no)
EE (1) EE9900528A (no)
HU (1) HUP0003392A3 (no)
IL (1) IL132882A0 (no)
IS (1) IS5247A (no)
NO (1) NO995617L (no)
NZ (1) NZ500974A (no)
PL (1) PL192521B1 (no)
SK (1) SK156099A3 (no)
TR (1) TR199902817T2 (no)
WO (1) WO1998052606A1 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1144010B1 (en) * 1999-01-08 2007-04-18 Wisconsin Alumni Research Foundation Prevention of chronic graft rejection by a combination of immunotoxins and costimulation blockers
JP3871503B2 (ja) * 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
ATE383873T1 (de) * 1999-10-22 2008-02-15 Biogen Idec Inc Verwendung eines cd40:cd154 bindungs- unterbrechers zur behandlung immunologischer komplikationen des auges
WO2001068133A1 (en) * 2000-03-14 2001-09-20 Genetics Institute, Inc. Use of rapamycin and agents that inhibit b7 activity in immunomodulation
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
BR0110779A (pt) 2000-05-12 2005-01-11 Beth Israel Hospital Composições e métodos para adquirir supressão imunológica
AU7541101A (en) * 2000-06-09 2001-12-24 Bristol Myers Squibb Co Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion
EP1179587A1 (de) * 2000-08-09 2002-02-13 Genethor GmbH Verfahren zur Reduzierung von spezifischen Immunreaktionen
CA2422076A1 (en) * 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
US9102726B2 (en) 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
CA2528551A1 (en) * 2003-06-13 2005-01-13 Biogen Idec Ma Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
MX2007001015A (es) 2004-07-26 2007-04-12 Biogen Idec Inc Anticuerpos anti-cd154.
WO2007043641A1 (ja) * 2005-10-14 2007-04-19 Fukuoka University 膵島移植における移植膵島障害抑制剤
US8945558B2 (en) * 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
AR057582A1 (es) * 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
US20070178087A1 (en) * 2005-12-15 2007-08-02 Christopher Roman Method for Treating Immune Dysfunction by Regulation of CD40 Ligand Expression
ES2685915T3 (es) * 2006-01-27 2018-10-15 Keio University Agentes terapéuticos para enfermedades que implican neovascularización coroidea
CN101495146B (zh) * 2006-04-07 2012-10-17 国立大学法人大阪大学 肌肉再生促进剂
TWI438208B (zh) * 2007-01-23 2014-05-21 Chugai Pharmaceutical Co Ltd 抑制慢性排斥反應之藥劑
TW201503898A (zh) * 2008-06-05 2015-02-01 Chugai Pharmaceutical Co Ltd 神經浸潤抑制劑
GB0815788D0 (en) * 2008-08-29 2008-10-08 Isis Innovation Therapeutic antibodies
HRP20221490T1 (hr) 2010-05-28 2023-02-03 Chugai Seiyaku Kabushiki Kaisha Poboljšanje antitumorskog odgovora t stanice
CA2969847A1 (en) 2014-12-10 2016-06-16 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
AU2016301361B2 (en) 2015-08-05 2022-06-16 Janssen Biotech, Inc. Anti-CD154 antibodies and methods of using them
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
WO2018217918A2 (en) 2017-05-24 2018-11-29 Als Therapy Development Institute Therapeutic anti-cd40 ligand antibodies
EP3698808A4 (en) 2017-10-20 2021-07-14 Hyogo College Of Medicine MEDICAL COMPOSITION CONTAINING ANTI-IL-6 RECEPTOR ANTIBODIES FOR THE PREVENTION OF POSTOPERATIVE ADHESION
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU201095B (en) * 1988-06-14 1990-09-28 Richter Gedeon Vegyeszet New peptides inhibiting the activity of the immune system and pharmaceutical compositions comprising same, as well as process for producing these peptides and compositions
US5104858A (en) * 1988-09-29 1992-04-14 Yale University Sensitizing multidrug resistant cells to antitumor agents
US5068323A (en) * 1989-04-21 1991-11-26 Merck & Co., Inc. Thermally re-arranged FK-506 derivatives having immunosuppressant activity
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
JPH08500826A (ja) * 1992-08-21 1996-01-30 ジェネンテク，インコーポレイテッド Ｌｆａ−１仲介疾患を処置する方法
JPH06298654A (ja) * 1993-04-12 1994-10-25 Sumitomo Electric Ind Ltd 抗原特異的免疫抑制剤
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US5916560A (en) * 1996-03-20 1999-06-29 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith
CN1248921A (zh) * 1997-01-10 2000-03-29 拜奥根有限公司 抗cd40l化合物的治疗性施用方法

Also Published As

Publication number Publication date
CN1261284A (zh) 2000-07-26
PL192521B1 (pl) 2006-11-30
IS5247A (is) 1999-11-12
CA2291156A1 (en) 1998-11-26
BG64841B1 (bg) 2006-06-30
EE9900528A (et) 2000-06-15
BR9809641A (pt) 2000-07-11
AU735592B2 (en) 2001-07-12
CN1202864C (zh) 2005-05-25
JP2002500648A (ja) 2002-01-08
EP0980259A1 (en) 2000-02-23
SK156099A3 (en) 2000-06-12
EA002549B1 (ru) 2002-06-27
NO995617D0 (no) 1999-11-16
AU7494098A (en) 1998-12-11
HUP0003392A3 (en) 2002-09-30
PL336994A1 (en) 2000-07-31
KR100575069B1 (ko) 2006-05-02
KR20010012671A (ko) 2001-02-26
HUP0003392A2 (hu) 2001-08-28
US20020119150A1 (en) 2002-08-29
WO1998052606A1 (en) 1998-11-26
US20070244053A1 (en) 2007-10-18
EA199901046A1 (ru) 2000-10-30
NZ500974A (en) 2001-06-29
TR199902817T2 (xx) 2000-09-21
BG103948A (en) 2000-07-31
IL132882A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
NO995617L (no) Anvendelse av en CD40:CD154 bindingsforstyrrer for å forhindre mot-adaptive immunresponser, spesielt transplantatavstoetning
PT1049695E (pt) Imidazotriazinonas 2-fenil substituidas enquanto inibidores de fosfodiesterase
PL338987A1 (en) 2-aminopyridines containing substituents in the form of condensed rings useful as nos inhibitors
IL148322A0 (en) Benzophenones as inhibitors of reverse transcriptase
IL135574A0 (en) Substituted 4-amino-thiazol-2-yl compounds as cdk inhibitors
PL362546A1 (en) Benzamide compounds as apo b secretion inhibitors
EE200200192A (et) 5-(2-asendatud-5-heterotsüklüülsulfonüülpürid-3-üül)dihüdropürasolo[4,3-d]pürimidii n-7-oonid kui fosfodiesteraasi inhibiitorid
AU8704101A (en) Novel cd40:cd154 binding interruptor compounds and use thereof to treat immunological complications
DK0818448T3 (da) Cycloalkanopyridiner som CETP-inhibitorer
EG21481A (en) Heteroaryl amines as novel acetylcholinesterase inhibitors
NO20004133L (no) Antistoffer mot human CD40
NO943852D0 (no) Fremgangsmåte for å hemme bentap
HK1048992A1 (zh) 作為激酶抑制劑的蝶啶酮
IL153661A0 (en) Piperidine compounds for use as ccr-3 inhibitors
NO20016319D0 (no) VLA-4 inhibitor-forbindelser
AU2745597A (en) Detergent compositions comprising modified polyamines as dye transfer inhibitors
ZA988469B (en) Pyrrolidin-2-one compounds and their use as neuraminidase inhibitors
DK1228073T3 (da) Imidazolforbindelser som phosphodiesterase VII-inhibitorer
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
SI1007512T1 (en) Branched alkoxy-subsituted 2-aminopyridines as nos inhibitors
NO922167D0 (no) Aminodukter som korrosjonshemmere
ZA91916B (en) Tricyclic-cyclic amines as novel cholinesterase inhibitors
IL148275A0 (en) Substituted 3-phenyl-5-alkoxy-1, 3, 4-oxdiazol-2-ones- and their use as lipase inhibitors
AU2001292276A1 (en) Nitrogen-containing compounds and ccr3 inhibitors containing the same as the active ingredient
AU2001225373A1 (en) Urea compounds as inhibitors for vla-4

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application